Dr. Jörn Grotjahn, M.St. (Oxf.)

Jörn advises on pharmaceutical supply and the adjacent fields of pharmaceutical law. His practice focuses on social law–based market regulation, particularly market access under the AMNOG procedure. His clients include both established pharmaceutical companies and emerging biotech startups. Jörn regularly speaks at professional conferences on topics relating to pharmaceutical supply and AMNOG. He is a contributor to the Nomos Commentary on Health Law, where he comments on AMNOG reimbursement negotiations, and is the author of numerous articles in specialist pharmaceutical law journals. According to JUVE, clients regard him as a “leading figure in AMNOG-related advice” and praise his “outstanding subject-matter expertise.”